melatonin has been researched along with Schizophrenia in 87 studies
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The sleep and circadian rhythm disruptions in schizophrenia are attributed to a decrease in nocturnal melatonin level which may worsen if treated with conventional sedative drugs." | 9.34 | Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: A randomized controlled trial. ( Jena, M; Maiti, R; Mishra, A; Mishra, BR; Nath, S; Sahu, P, 2020) |
| " Amelioration of cognitive dysfunction may be facilitated during benzodiazepine tapering by add-on melatonin due to its anti-inflammatory and neuroprotective properties." | 9.24 | Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. ( Baandrup, L; Fagerlund, B; Glenthoj, B, 2017) |
| "Melatonin/ramelteon augmentation may be beneficial for non-anthropometric metabolic syndrome components in patients treated with antipsychotics." | 9.22 | Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis. ( Fornaro, M; Miola, A; Sambataro, F; Solmi, M, 2022) |
| "We assessed if prolonged-release melatonin can facilitate withdrawal of long-term benzodiazepine usage in patients with schizophrenia or bipolar disorder." | 9.22 | Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial. ( Baandrup, L; Glenthoj, BY; Gluud, C; Lindschou, J; Winkel, P, 2016) |
| "The results from this trial will examine whether melatonin has a role in withdrawing long-term benzodiazepine administration in schizophrenia patients." | 9.15 | Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. ( Baandrup, L; Fagerlund, B; Glenthoj, BY; Gluud, C; Hansen, JL; Jennum, P; Lublin, H; Oranje, B; Winkel, P, 2011) |
| "Nocturnal hormone profiles were measured in patients with schizophrenia with predominantly negative symptoms both under drug-free baseline conditions and after subchronic administration of the atypical antipsychotic olanzapine, with the aim of characterizing its pharmacological properties on the neuroendocrine level." | 9.12 | Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. ( Dittmann, RW; Hiemke, C; Linde, I; Mann, K; Müller, MJ; Müller-Siecheneder, F; Pott, T; Rossbach, W, 2006) |
| "In a randomized, double-blind, cross-over, clinically based trial, 19 patients with DSM-IV schizophrenia who were treated with the normal treatment regimen were given melatonin (2 mg, controlled release) or placebo for 2 treatment periods of 3 weeks each with 1 week washout between treatment periods (7 weeks total)." | 9.09 | Melatonin improves sleep quality of patients with chronic schizophrenia. ( Anis, Y; Barak, Y; Elizur, A; Laudon, M; Rotenberg, V; Shamir, E; Zisapel, N, 2000) |
| "This paper reviews melatonin as an overlooked factor in the developmental etiology and maintenance of schizophrenia; the neuroimmune and oxidative pathophysiology of schizophrenia; specific symptoms in schizophrenia, including sleep disturbance; circadian rhythms; and side effects of antipsychotics, including tardive dyskinesia and metabolic syndrome." | 8.88 | Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. ( Anderson, G; Maes, M, 2012) |
| "An emerging area in schizophrenia research focuses on the impact of immunomodulatory drugs such as melatonin, which have played important roles in many biological systems and functions, and appears to be promising." | 7.96 | Schizophrenia-like behavior is not altered by melatonin supplementation in rodents. ( Afonso, AC; Bialecki, AVS; Bischoff, LM; Canever, L; Godoi, AK; Hubbe, I; Mastella, GA; Pacheco, FD; Wessler, PG; Zugno, AI, 2020) |
| "Melatonin, a neuro-differentiation factor, may play a role in the neurodevelopmental origins of schizophrenia." | 7.91 | Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia. ( Guloksuz, S; Kırpınar, I; Kurtulmus, A; Özer, OF; Sahbaz, C; Sahin, F, 2019) |
| "Melatonin is a neurohormone that is linked to the pathogenesis of schizophrenia." | 7.91 | Reversal of Schizophrenia-like Symptoms and Cholinergic Alterations by Melatonin. ( Akram, M; Andrabi, SS; Kaushik, M; Parveen, K; Parvez, S; Tabassum, H; Vishnoi, S, 2019) |
| "Melatonin is a neurohormone that is linked to the aetiopathogenesis of schizophrenia." | 7.85 | Melatonin attenuates behavioural deficits and reduces brain oxidative stress in a rodent model of schizophrenia. ( Aina, OA; Onaolapo, AY; Onaolapo, OJ, 2017) |
| "The results of the present study indicate that endogenous melatonin sleep-promoting action seems to be compromised in schizophrenia." | 7.77 | Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls. ( Afonso, P; Figueira, ML; Paiva, T, 2011) |
| "The atypical antipsychotic drug olanzapine increases body weight and visceral adiposity in schizophrenia." | 7.74 | Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. ( Burke, BL; Crites, NJ; Raskind, MA; Rasmussen, DD; Tapp, AM, 2007) |
| " In communicating hydrocephalus, the function of the tela choroidae could be impaired by infectious or inflammatory processes; while in schizophrenia a physiologic disorder of cerebrospinal fluid production due to a melatonin deficiency may result in dilated ventricles." | 7.67 | The pathophysiology of enlarged ventricles in normal pressure communicating hydrocephalus and schizophrenia: a possible therapeutic role for melatonin. ( Maurizi, CP, 1987) |
| " Reduced benzodiazepine dosage at the 24-week follow-up was associated with a significantly decreased proportion of stage 2 sleep." | 6.82 | Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. ( Baandrup, L; Glenthøj, BY; Jennum, PJ, 2016) |
| "Schizophrenia and mood disorders are the two major psychiatric disorders." | 6.53 | The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment. ( Demirci, K; Espino, J; Uguz, AC, 2016) |
| "Melatonin has been involved in schizophrenia since the first decades of the twentieth century." | 6.49 | Role of melatonin in schizophrenia. ( Abreu-Gonzalez, P; Morera-Fumero, AL, 2013) |
| "Schizophrenia is characterized by complex and dynamically interacting perturbations in multiple neurochemical systems." | 5.36 | Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. ( Dougherty, GG; Kaddurah-Daouk, R; Keshavan, MS; Krishnan, RR; Matson, WR; McEvoy, J; Montrose, DM; Reddy, RD; Rozen, S; Yao, JK, 2010) |
| "The sleep and circadian rhythm disruptions in schizophrenia are attributed to a decrease in nocturnal melatonin level which may worsen if treated with conventional sedative drugs." | 5.34 | Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: A randomized controlled trial. ( Jena, M; Maiti, R; Mishra, A; Mishra, BR; Nath, S; Sahu, P, 2020) |
| "Melatonin was estimated by RIA in samples taken at 24." | 5.26 | Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. ( Arendt, J; Crow, TJ; Ferrier, IN; Johnstone, EC, 1982) |
| "In primary biliary cirrhosis there are increased skin pigmentation, hepatic fibrosis, elevated cholesterol and alkaline phosphatase levels, defective T lymphocytes and hyperactive B lymphocytes." | 5.26 | The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. ( Cunnane, SC; Horrobin, DF; Manku, MS, 1979) |
| "Propranolol in plasma was positively correlated to dosage." | 5.26 | Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings. ( Alfredsson, G; Hanssen, T; Heyden, T; Nybäck, H; Sundberg, I; Wetterberg, L, 1980) |
| " Amelioration of cognitive dysfunction may be facilitated during benzodiazepine tapering by add-on melatonin due to its anti-inflammatory and neuroprotective properties." | 5.24 | Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. ( Baandrup, L; Fagerlund, B; Glenthoj, B, 2017) |
| "There is low-certainty evidence to suggest that metformin may be effective in preventing weight gain." | 5.22 | Pharmacological interventions for prevention of weight gain in people with schizophrenia. ( Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH, 2022) |
| "We assessed if prolonged-release melatonin can facilitate withdrawal of long-term benzodiazepine usage in patients with schizophrenia or bipolar disorder." | 5.22 | Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial. ( Baandrup, L; Glenthoj, BY; Gluud, C; Lindschou, J; Winkel, P, 2016) |
| "Melatonin/ramelteon augmentation may be beneficial for non-anthropometric metabolic syndrome components in patients treated with antipsychotics." | 5.22 | Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis. ( Fornaro, M; Miola, A; Sambataro, F; Solmi, M, 2022) |
| "The results from this trial will examine whether melatonin has a role in withdrawing long-term benzodiazepine administration in schizophrenia patients." | 5.15 | Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. ( Baandrup, L; Fagerlund, B; Glenthoj, BY; Gluud, C; Hansen, JL; Jennum, P; Lublin, H; Oranje, B; Winkel, P, 2011) |
| "Nocturnal hormone profiles were measured in patients with schizophrenia with predominantly negative symptoms both under drug-free baseline conditions and after subchronic administration of the atypical antipsychotic olanzapine, with the aim of characterizing its pharmacological properties on the neuroendocrine level." | 5.12 | Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. ( Dittmann, RW; Hiemke, C; Linde, I; Mann, K; Müller, MJ; Müller-Siecheneder, F; Pott, T; Rossbach, W, 2006) |
| "Using a double-blind, placebo-controlled, crossover study, we evaluated the efficacy of 10 mg/d of melatonin for 6 weeks in 22 patients with schizophrenia and TD." | 5.09 | Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. ( Barak, Y; Elizur, A; Laudon, M; Shalman, I; Shamir, E; Tarrasch, R; Weizman, R; Zisapel, N, 2001) |
| " On the basis of recent studies showing some benefit of antioxidants, we evaluated the effect of melatonin, the most potent naturally occurring antioxidant, on tardive dyskinesia in patients with chronic schizophrenia." | 5.09 | Is melatonin treatment effective for tardive dyskinesia? ( Barak, Y; Elizur, A; Plopsky, I; Shamir, E; Weizman, A; Zisapel, N, 2000) |
| "In a randomized, double-blind, cross-over, clinically based trial, 19 patients with DSM-IV schizophrenia who were treated with the normal treatment regimen were given melatonin (2 mg, controlled release) or placebo for 2 treatment periods of 3 weeks each with 1 week washout between treatment periods (7 weeks total)." | 5.09 | Melatonin improves sleep quality of patients with chronic schizophrenia. ( Anis, Y; Barak, Y; Elizur, A; Laudon, M; Rotenberg, V; Shamir, E; Zisapel, N, 2000) |
| "To evaluate the biosynthetic activity of the pineal gland in schizophrenia, the circadian rhythm of plasma melatonin was investigated in 9 drug-free chronic schizophrenics and in matched healthy subjects." | 5.08 | Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. ( La Rocca, A; Maj, M; Monteleone, P; Natale, M, 1997) |
| "Despite a very limited number of specific studies on this matter, all 4 studies have shown good benefit/risk ratios and reviewed options-melatonin, paliperidone, and eszopiclone-might represent valid options for residual insomnia in schizophrenia." | 5.01 | Treatment Options for Insomnia in Schizophrenia: A Systematic Review. ( Coroa, M; Madeira, N; Oliveira, P, 2019) |
| "This paper reviews melatonin as an overlooked factor in the developmental etiology and maintenance of schizophrenia; the neuroimmune and oxidative pathophysiology of schizophrenia; specific symptoms in schizophrenia, including sleep disturbance; circadian rhythms; and side effects of antipsychotics, including tardive dyskinesia and metabolic syndrome." | 4.88 | Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. ( Anderson, G; Maes, M, 2012) |
| "An emerging area in schizophrenia research focuses on the impact of immunomodulatory drugs such as melatonin, which have played important roles in many biological systems and functions, and appears to be promising." | 3.96 | Schizophrenia-like behavior is not altered by melatonin supplementation in rodents. ( Afonso, AC; Bialecki, AVS; Bischoff, LM; Canever, L; Godoi, AK; Hubbe, I; Mastella, GA; Pacheco, FD; Wessler, PG; Zugno, AI, 2020) |
| "Melatonin is a neurohormone that is linked to the pathogenesis of schizophrenia." | 3.91 | Reversal of Schizophrenia-like Symptoms and Cholinergic Alterations by Melatonin. ( Akram, M; Andrabi, SS; Kaushik, M; Parveen, K; Parvez, S; Tabassum, H; Vishnoi, S, 2019) |
| "Melatonin, a neuro-differentiation factor, may play a role in the neurodevelopmental origins of schizophrenia." | 3.91 | Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia. ( Guloksuz, S; Kırpınar, I; Kurtulmus, A; Özer, OF; Sahbaz, C; Sahin, F, 2019) |
| "Melatonin is a neurohormone that is linked to the aetiopathogenesis of schizophrenia." | 3.85 | Melatonin attenuates behavioural deficits and reduces brain oxidative stress in a rodent model of schizophrenia. ( Aina, OA; Onaolapo, AY; Onaolapo, OJ, 2017) |
| "Immune dysregulation observed in schizophrenia alters tryptophan metabolism." | 3.85 | Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs. ( Cordeiro, RC; da Silva Araújo, T; de Freitas Lima, R; de Jesus Souza Machado, M; Freitas de Lucena, D; Isabelle de Góis Queiroz, A; Macêdo, D; Maes, M; Maia Chaves Filho, AJ; Monte, AS, 2017) |
| "Although melatonin has been implicated in several neurophysiological systems, data on the relationship of melatonin with psychosis such as schizophrenia are limited and contradictory." | 3.79 | Chronic melatonin treatment reverses disruption of prepulse inhibition in pinealectomized and pinealectomized-plus-ovariectomized rats. ( Acet, A; Akdag, E; Celik, T; Kayir, H; Kose, A; Parlakpinar, H; Ulusoy, G; Uzbay, T; Yararbas, G, 2013) |
| "We examined the relationship between sleep-wake activity, recorded actigraphically over 6 weeks, along with ambient light exposure and simultaneous circadian clock timing, by collecting weekly 48 h profiles of a urinary metabolite of melatonin in 20 out-patients with schizophrenia and 21 healthy control individuals matched for age, gender and being unemployed." | 3.78 | Sleep and circadian rhythm disruption in schizophrenia. ( Dijk, DJ; Foster, RG; Joyce, EM; Middleton, B; Wulff, K, 2012) |
| "The results of the present study indicate that endogenous melatonin sleep-promoting action seems to be compromised in schizophrenia." | 3.77 | Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls. ( Afonso, P; Figueira, ML; Paiva, T, 2011) |
| "Sleep-wake cycles in individuals with schizophrenia ranged from well entrained to highly disturbed rhythms with fragmented sleep epochs, together with delayed melatonin onsets and higher levels of daytime sleepiness." | 3.77 | Sleep-wake cycles and cognitive functioning in schizophrenia. ( Bromundt, V; Cajochen, C; Georgiev-Kill, A; Köster, M; Opwis, K; Stoppe, G; Wirz-Justice, A, 2011) |
| "The atypical antipsychotic drug olanzapine increases body weight and visceral adiposity in schizophrenia." | 3.74 | Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. ( Burke, BL; Crites, NJ; Raskind, MA; Rasmussen, DD; Tapp, AM, 2007) |
| "A haloperidol-treated patient with chronic schizophrenia had a near-arrhythmic circadian rest-activity cycle, whereas rhythms of 6-sulphatoxy-melatonin and core body temperature were of normal amplitude and phase-advanced." | 3.69 | A schizophrenic patient with an arrhythmic circadian rest-activity cycle. ( Cajochen, C; Nussbaum, P; Wirz-Justice, A, 1997) |
| " In communicating hydrocephalus, the function of the tela choroidae could be impaired by infectious or inflammatory processes; while in schizophrenia a physiologic disorder of cerebrospinal fluid production due to a melatonin deficiency may result in dilated ventricles." | 3.67 | The pathophysiology of enlarged ventricles in normal pressure communicating hydrocephalus and schizophrenia: a possible therapeutic role for melatonin. ( Maurizi, CP, 1987) |
| " Reduced benzodiazepine dosage at the 24-week follow-up was associated with a significantly decreased proportion of stage 2 sleep." | 2.82 | Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. ( Baandrup, L; Glenthøj, BY; Jennum, PJ, 2016) |
| "Stable DSM-IV schizophrenic outpatients (N = 40) with initial insomnia of at least 2 weeks' duration were randomly assigned to augment their current medications with either flexibly dosed melatonin (3-12 mg/night; N = 20) or placebo (N = 20)." | 2.73 | Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. ( Andrade, C; Bhakta, SG; Singh, NM; Suresh Kumar, PN, 2007) |
| "The prevalence of type 2 diabetes is increased in individuals with mental disorders." | 2.72 | Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries. ( Ajjan, RA; Al Azdi, Z; Aslam, F; Churchill, R; Mishu, MP; Philip, S; Siddiqi, N; Stubbs, B; Tirbhowan, N; Uphoff, E; Wright, J, 2021) |
| "Schizophrenia and mood disorders are the two major psychiatric disorders." | 2.53 | The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment. ( Demirci, K; Espino, J; Uguz, AC, 2016) |
| "Schizophrenia is a chronic condition that impacts significantly not only on the individual and family, but the disorder also has wider consequences for society in terms of significant costs to the economy." | 2.50 | Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. ( Arroll, MA; Neil, J; Wilder, L, 2014) |
| "Melatonin has been involved in schizophrenia since the first decades of the twentieth century." | 2.49 | Role of melatonin in schizophrenia. ( Abreu-Gonzalez, P; Morera-Fumero, AL, 2013) |
| "In untreated schizophrenia, psychotic decompensation is associated with profound insomnia, one of the prodromal symptoms associated with psychotic relapse." | 2.43 | Sleep in schizophrenia: impairments, correlates, and treatment. ( Benson, KL, 2006) |
| "In melatonin treated rats, prefrontal tissue malondialdehyde and protein carbonyl levels were decreased significantly in comparison with MK-801 group (p < 0." | 1.40 | Potential role of some oxidant/antioxidant status parameters in prefrontal cortex of rat brain in an experimental psychosis model and the protective effects of melatonin. ( Akyol, O; Kus, I; Ozyurt, B; Ozyurt, H; Sarsilmaz, M; Songur, A, 2014) |
| "Schizophrenia is characterized by complex and dynamically interacting perturbations in multiple neurochemical systems." | 1.36 | Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. ( Dougherty, GG; Kaddurah-Daouk, R; Keshavan, MS; Krishnan, RR; Matson, WR; McEvoy, J; Montrose, DM; Reddy, RD; Rozen, S; Yao, JK, 2010) |
| "Melatonin secretion has been suggested as a marker of both circadian and noradrenergic dysfunction in affective disorders." | 1.28 | Nocturnal melatonin and cortisol secretion in newly admitted psychiatric inpatients. Implications for affective disorders. ( Brown, GM; Goldman, S; Steiner, M, 1990) |
| "Melatonin was estimated by RIA in samples taken at 24." | 1.26 | Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight. ( Arendt, J; Crow, TJ; Ferrier, IN; Johnstone, EC, 1982) |
| "Propranolol in plasma was positively correlated to dosage." | 1.26 | Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings. ( Alfredsson, G; Hanssen, T; Heyden, T; Nybäck, H; Sundberg, I; Wetterberg, L, 1980) |
| "In primary biliary cirrhosis there are increased skin pigmentation, hepatic fibrosis, elevated cholesterol and alkaline phosphatase levels, defective T lymphocytes and hyperactive B lymphocytes." | 1.26 | The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. ( Cunnane, SC; Horrobin, DF; Manku, MS, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (21.84) | 18.7374 |
| 1990's | 13 (14.94) | 18.2507 |
| 2000's | 15 (17.24) | 29.6817 |
| 2010's | 35 (40.23) | 24.3611 |
| 2020's | 5 (5.75) | 2.80 |
| Authors | Studies |
|---|---|
| Miola, A | 1 |
| Fornaro, M | 1 |
| Sambataro, F | 1 |
| Solmi, M | 1 |
| Agarwal, SM | 1 |
| Stogios, N | 1 |
| Ahsan, ZA | 1 |
| Lockwood, JT | 1 |
| Duncan, MJ | 1 |
| Takeuchi, H | 1 |
| Cohn, T | 1 |
| Taylor, VH | 1 |
| Remington, G | 1 |
| Faulkner, GEJ | 1 |
| Hahn, M | 1 |
| Andrabi, SS | 1 |
| Vishnoi, S | 1 |
| Kaushik, M | 1 |
| Parveen, K | 1 |
| Tabassum, H | 1 |
| Akram, M | 1 |
| Parvez, S | 1 |
| Mishra, A | 1 |
| Maiti, R | 1 |
| Mishra, BR | 1 |
| Jena, M | 1 |
| Nath, S | 1 |
| Sahu, P | 1 |
| Afonso, AC | 1 |
| Pacheco, FD | 1 |
| Canever, L | 1 |
| Wessler, PG | 1 |
| Mastella, GA | 1 |
| Godoi, AK | 1 |
| Hubbe, I | 1 |
| Bischoff, LM | 1 |
| Bialecki, AVS | 1 |
| Zugno, AI | 1 |
| Mishu, MP | 1 |
| Uphoff, E | 1 |
| Aslam, F | 1 |
| Philip, S | 1 |
| Wright, J | 1 |
| Tirbhowan, N | 1 |
| Ajjan, RA | 1 |
| Al Azdi, Z | 1 |
| Stubbs, B | 1 |
| Churchill, R | 1 |
| Siddiqi, N | 1 |
| Galván-Arrieta, T | 2 |
| Trueta, C | 2 |
| Cercós, MG | 2 |
| Valdés-Tovar, M | 2 |
| Alarcón, S | 1 |
| Oikawa, J | 1 |
| Zamudio-Meza, H | 1 |
| Benítez-King, G | 3 |
| Onaolapo, AY | 1 |
| Aina, OA | 1 |
| Onaolapo, OJ | 1 |
| Solís-Chagoyán, H | 1 |
| Argueta, J | 1 |
| Oliveira, P | 1 |
| Coroa, M | 1 |
| Madeira, N | 1 |
| Sahbaz, C | 1 |
| Özer, OF | 1 |
| Kurtulmus, A | 1 |
| Kırpınar, I | 1 |
| Sahin, F | 1 |
| Guloksuz, S | 1 |
| Bastos, MAV | 1 |
| Oliveira Bastos, PRH | 1 |
| Portella, RB | 1 |
| Soares, LFG | 1 |
| Conde, RB | 1 |
| Rodrigues, PMF | 1 |
| Lucchetti, G | 1 |
| Morera-Fumero, AL | 1 |
| Abreu-Gonzalez, P | 1 |
| Modabbernia, A | 1 |
| Heidari, P | 1 |
| Soleimani, R | 1 |
| Sobhani, A | 1 |
| Roshan, ZA | 1 |
| Taslimi, S | 1 |
| Ashrafi, M | 1 |
| Modabbernia, MJ | 1 |
| Lehtinen, EK | 1 |
| Ucar, E | 1 |
| Glenthøj, BY | 2 |
| Oranje, B | 2 |
| Ozyurt, H | 1 |
| Ozyurt, B | 1 |
| Sarsilmaz, M | 1 |
| Kus, I | 1 |
| Songur, A | 1 |
| Akyol, O | 1 |
| Arroll, MA | 1 |
| Wilder, L | 1 |
| Neil, J | 1 |
| Schwartz, PJ | 2 |
| Baandrup, L | 5 |
| Lindschou, J | 1 |
| Winkel, P | 2 |
| Gluud, C | 2 |
| Glenthoj, BY | 2 |
| Jennum, PJ | 1 |
| Uguz, AC | 1 |
| Demirci, K | 1 |
| Espino, J | 1 |
| Fagerlund, B | 2 |
| Glenthoj, B | 2 |
| da Silva Araújo, T | 1 |
| Maia Chaves Filho, AJ | 1 |
| Monte, AS | 1 |
| Isabelle de Góis Queiroz, A | 1 |
| Cordeiro, RC | 1 |
| de Jesus Souza Machado, M | 1 |
| de Freitas Lima, R | 1 |
| Freitas de Lucena, D | 1 |
| Maes, M | 2 |
| Macêdo, D | 1 |
| Vanelle, JM | 1 |
| Yao, JK | 1 |
| Dougherty, GG | 1 |
| Reddy, RD | 1 |
| Keshavan, MS | 1 |
| Montrose, DM | 1 |
| Matson, WR | 1 |
| Rozen, S | 1 |
| Krishnan, RR | 1 |
| McEvoy, J | 1 |
| Kaddurah-Daouk, R | 1 |
| Kantrowitz, J | 1 |
| Citrome, L | 1 |
| Javitt, D | 1 |
| Trbovic, SM | 1 |
| Bernstein, HG | 1 |
| Heinemann, A | 1 |
| Steiner, J | 1 |
| Bogerts, B | 1 |
| Afonso, P | 2 |
| Brissos, S | 1 |
| Figueira, ML | 2 |
| Paiva, T | 2 |
| Lamont, EW | 1 |
| Coutu, DL | 1 |
| Cermakian, N | 1 |
| Boivin, DB | 1 |
| Anderson, G | 2 |
| Bromundt, V | 2 |
| Köster, M | 1 |
| Georgiev-Kill, A | 1 |
| Opwis, K | 1 |
| Wirz-Justice, A | 2 |
| Stoppe, G | 1 |
| Cajochen, C | 2 |
| Marzullo, G | 1 |
| Boklage, CE | 1 |
| Lerner, V | 1 |
| Miodownik, C | 1 |
| Jennum, P | 2 |
| Lublin, H | 2 |
| Hansen, JL | 1 |
| Wulff, K | 2 |
| Dijk, DJ | 2 |
| Middleton, B | 2 |
| Foster, RG | 2 |
| Joyce, EM | 1 |
| Uzbay, T | 1 |
| Parlakpinar, H | 1 |
| Akdag, E | 1 |
| Celik, T | 1 |
| Yararbas, G | 1 |
| Ulusoy, G | 1 |
| Acet, A | 1 |
| Kose, A | 1 |
| Kayir, H | 1 |
| Andrade, C | 2 |
| Suresh Kumar, PN | 2 |
| Monti, JM | 1 |
| BaHammam, AS | 1 |
| Pandi-Perumal, SR | 1 |
| Spence, DW | 1 |
| Cardinali, DP | 1 |
| Brown, GM | 2 |
| Abbott, A | 1 |
| Erk, SD | 1 |
| Ramírez-Rodríguez, G | 1 |
| Ortíz, L | 1 |
| Meza, I | 1 |
| Mann, K | 1 |
| Rossbach, W | 1 |
| Müller, MJ | 1 |
| Müller-Siecheneder, F | 1 |
| Pott, T | 1 |
| Linde, I | 1 |
| Dittmann, RW | 1 |
| Hiemke, C | 1 |
| Joyce, E | 1 |
| Raskind, MA | 1 |
| Burke, BL | 1 |
| Crites, NJ | 1 |
| Tapp, AM | 1 |
| Rasmussen, DD | 1 |
| Benson, KL | 1 |
| Bhakta, SG | 1 |
| Singh, NM | 1 |
| Ferrier, IN | 2 |
| Johnstone, EC | 2 |
| Crow, TJ | 2 |
| Arendt, J | 2 |
| Wetterberg, L | 3 |
| Aperia, B | 1 |
| Beck-Friis, J | 1 |
| Kjellman, BF | 1 |
| Ljunggren, JG | 1 |
| Nilsonne, A | 1 |
| Petterson, U | 1 |
| Tham, A | 1 |
| Undén, F | 1 |
| Backon, J | 1 |
| Hadjiconstantinou, M | 1 |
| Neff, NH | 1 |
| Hanssen, T | 2 |
| Heyden, T | 2 |
| Sundberg, I | 2 |
| Alfredsson, G | 1 |
| Nybäck, H | 1 |
| Monteleone, P | 2 |
| Piccolo, A | 1 |
| Martino, M | 1 |
| Maj, M | 2 |
| Rao, ML | 1 |
| Gross, G | 1 |
| Strebel, B | 1 |
| Halaris, A | 1 |
| Huber, G | 1 |
| Bräunig, P | 1 |
| Marler, M | 1 |
| Bozhko, GKh | 1 |
| Tsaritsinskiĭ, VI | 1 |
| Kulabukhov, VM | 1 |
| Taranskaia, AD | 1 |
| Silver, H | 1 |
| Barash, I | 1 |
| Odnopozov, N | 1 |
| Jahjah, N | 1 |
| Mizruhin, A | 1 |
| Natale, M | 1 |
| La Rocca, A | 1 |
| Nussbaum, P | 1 |
| Jiang, HK | 1 |
| Wang, JY | 1 |
| Shamir, E | 4 |
| Laudon, M | 3 |
| Barak, Y | 3 |
| Anis, Y | 1 |
| Rotenberg, V | 1 |
| Elizur, A | 4 |
| Zisapel, N | 4 |
| Plopsky, I | 1 |
| Weizman, A | 1 |
| Rotenberg, VS | 1 |
| Viganò, D | 1 |
| Lissoni, P | 1 |
| Rovelli, F | 1 |
| Roselli, MG | 1 |
| Malugani, F | 1 |
| Gavazzeni, C | 1 |
| Conti, A | 1 |
| Maestroni, G | 1 |
| Shalman, I | 1 |
| Tarrasch, R | 1 |
| Weizman, R | 1 |
| Horrobin, DF | 2 |
| Cunnane, SC | 1 |
| Manku, MS | 1 |
| Mullen, PE | 1 |
| Silman, RE | 1 |
| Smythies, JR | 1 |
| Sandyk, R | 3 |
| Kay, SR | 3 |
| Markey, SP | 1 |
| Boni, RL | 1 |
| Yergey, JA | 1 |
| Heyes, MP | 1 |
| Robinson, S | 1 |
| Rosca, P | 1 |
| Durst, R | 1 |
| Shai, U | 1 |
| Ghinea, C | 1 |
| Schmidt, U | 1 |
| Nir, I | 1 |
| Steiner, M | 1 |
| Goldman, S | 1 |
| Souêtre, E | 1 |
| Salvati, E | 1 |
| Krebs, B | 1 |
| Belugou, JL | 1 |
| Darcourt, G | 1 |
| Fanget, F | 1 |
| Claustrat, B | 1 |
| Dalery, J | 1 |
| Brun, J | 1 |
| Terra, JL | 1 |
| Marie-Cardine, M | 1 |
| Guyotat, J | 1 |
| Miles, A | 2 |
| Philbrick, DR | 1 |
| Philbrick, D | 1 |
| Maurizi, CP | 1 |
| Jones, RL | 1 |
| McGeer, PL | 1 |
| Greiner, AC | 1 |
| Johnston, VS | 1 |
| Bradley, RJ | 1 |
| Grener, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of Bupropion SR and Placebo for Smoking Cessation[NCT00176449] | Phase 4 | 52 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| Phase 2 Study of Melatonin Adjunct to Olanzapine for Prevention of Olanzapine-associated Metabolic Side Effects.[NCT01593774] | Phase 2 | 36 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia[NCT03075657] | Phase 4 | 120 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial[NCT01431092] | Phase 4 | 86 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia[NCT00505765] | Phase 2 | 63 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504] | Phase 4 | 25 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality[NCT00512070] | 20 participants (Anticipated) | Interventional | 2007-07-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 3.9 |
| AL-108, 5 mg/Day | 4.6 |
| Placebo | 3.2 |
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 1.3 |
| AL-108, 5 mg/Day | 2.3 |
| Placebo | -0.2 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | -0.4 |
| AL-108, 5 mg/Day | -1.2 |
| Placebo | -0.3 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 0.1 |
| AL-108, 5 mg/Day | -0.6 |
| Placebo | -0.1 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 4.9 |
| AL-108, 5 mg/Day | 8.9 |
| Placebo | 0.3 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 2.9 |
| AL-108, 5 mg/Day | 7.2 |
| Placebo | -0.9 |
A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | g (Mean) |
|---|---|
| Ramelteon | 3934.86 |
| Placebo (Sugar Pill) | 5120.92 |
A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Ramelteon | 2.4 |
| Placebo (Sugar Pill) | 2.36 |
A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8
| Intervention | cm (Mean) |
|---|---|
| Ramelteon | 106.09 |
| Placebo (Sugar Pill) | 108.37 |
25 reviews available for melatonin and Schizophrenia
| Article | Year |
|---|---|
Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis.
Topics: Antipsychotic Agents; Bipolar Disorder; Humans; Melatonin; Metabolic Syndrome; Randomized Controlled | 2022 |
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Topics: Antipsychotic Agents; Betahistine; Famotidine; Fluoxetine; Humans; Melatonin; Metformin; Nausea; Niz | 2022 |
Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antioxidants; Antipsychotic Agents; Blood Glucose; Bo | 2021 |
Treatment Options for Insomnia in Schizophrenia: A Systematic Review.
Topics: Eszopiclone; Humans; Hypnotics and Sedatives; Melatonin; Odds Ratio; Paliperidone Palmitate; Schizop | 2019 |
Pineal gland and schizophrenia: A systematic review and meta-analysis.
Topics: Circadian Rhythm; Female; Humans; Magnetic Resonance Imaging; Male; Melatonin; Pineal Gland; Schizop | 2019 |
Role of melatonin in schizophrenia.
Topics: Biomarkers; Humans; Melatonin; Schizophrenia | 2013 |
Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review.
Topics: Acetylcysteine; Antipsychotic Agents; Ascorbic Acid; Databases, Factual; Diet, Gluten-Free; Dietary | 2014 |
The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment.
Topics: Anticonvulsants; Antipsychotic Agents; Circadian Rhythm; Humans; Melatonin; Mitochondria; Mood Disor | 2016 |
[Schizophrenia and circadian rhythms].
Topics: Acute Disease; Antipsychotic Agents; Circadian Rhythm; Humans; Melatonin; Recurrence; Schizophrenia; | 2009 |
GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications.
Topics: Animals; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Depressants; Central Ner | 2009 |
Circadian rhythms and clock genes in psychotic disorders.
Topics: Animals; Bipolar Disorder; Circadian Rhythm; CLOCK Proteins; Glycogen Synthase Kinase 3; Humans; Lit | 2010 |
Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Fatty Acids, Omega-3; Ginkgo biloba; Humans; Levetira | 2011 |
Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects.
Topics: Antioxidants; Antipsychotic Agents; Humans; Melatonin; Schizophrenia; Sleep; Vitamin D | 2012 |
Treatment options for residual insomnia in schizophrenia.
Topics: Antipsychotic Agents; Central Nervous System Depressants; Humans; Isoxazoles; Melatonin; Paliperidon | 2013 |
Sleep and circadian rhythm dysregulation in schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Circadian Rhythm; Humans; Melatonin; Schizophrenia; Schizophr | 2013 |
The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia.
Topics: Animals; Brain; Cytoskeleton; Humans; Lewy Bodies; Melatonin; Microtubule-Associated Proteins; Neuro | 2004 |
Sleep in schizophrenia: impairments, correlates, and treatment.
Topics: Antioxidants; Antipsychotic Agents; Humans; Melatonin; Schizophrenia; Sleep Wake Disorders | 2006 |
Catecholamine systems of retina: a model for studying synaptic mechanisms.
Topics: Adenylyl Cyclases; Adrenergic alpha-Agonists; Animals; Antipsychotic Agents; Darkness; Dopamine; Ele | 1984 |
Biochemical abnormalities associated with schizophrenia.
Topics: Amino Acids, Essential; Brain; Catecholamines; Depression, Chemical; Hallucinogens; Humans; Lysergic | 1975 |
The relationship of pineal calcification and melatonin secretion to the pathophysiology of tardive dyskinesia and Tourette's syndrome.
Topics: Adult; Aged; Bipolar Disorder; Calcinosis; Dyskinesia, Drug-Induced; Female; Humans; Male; Melatonin | 1991 |
Mass spectrometric determinations of tryptophan and its metabolites.
Topics: Animals; Body Fluids; Gas Chromatography-Mass Spectrometry; Humans; Mass Spectrometry; Melatonin; Mo | 1991 |
Pineal melatonin in schizophrenia: a review and hypothesis.
Topics: Dyskinesia, Drug-Induced; Humans; Melatonin; Pineal Gland; Risk Factors; Schizophrenia; Schizophreni | 1990 |
Melatonin and psychiatry.
Topics: Animals; Antidepressive Agents; Brain; Chronobiology Phenomena; Depressive Disorder; Humans; Melaton | 1988 |
Melatonin: perspectives in laboratory medicine and clinical research.
Topics: Brain Neoplasms; Breast Neoplasms; Humans; Male; Melanoma; Melatonin; Mood Disorders; Prostatic Neop | 1987 |
Molecular pharmacology of hallucinogens.
Topics: Amphetamine; Animals; Avoidance Learning; Brain; Conditioning, Operant; Emotions; Hallucinogens; Hum | 1968 |
16 trials available for melatonin and Schizophrenia
| Article | Year |
|---|---|
Effect of add-on ramelteon therapy on sleep and circadian rhythm disruption in patients with schizophrenia: A randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Circadian Rhythm; Drug Therapy, Combination; Female; Follow-Up Studies; | 2020 |
Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antioxidants; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; F | 2014 |
Effects of melatonin on prepulse inhibition, habituation and sensitization of the human startle reflex in healthy volunteers.
Topics: Adolescent; Adult; Attention; Cross-Over Studies; Habituation, Psychophysiologic; Healthy Volunteers | 2014 |
Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: A randomised, placebo-controlled, blinded trial.
Topics: Adult; Aged; Benzodiazepines; Bipolar Disorder; Denmark; Double-Blind Method; Female; Humans; Logist | 2016 |
Objective and subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Central Nervous System Depressants; | 2016 |
Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo.
Topics: Adult; Antioxidants; Benzodiazepines; Bipolar Disorder; Cognitive Dysfunction; Double-Blind Method; | 2017 |
Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clinical Protocols; Delayed-Action Prepara | 2011 |
Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clinical Protocols; Delayed-Action Prepara | 2011 |
Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clinical Protocols; Delayed-Action Prepara | 2011 |
Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clinical Protocols; Delayed-Action Prepara | 2011 |
Regulation of central dopamine-2 receptor sensitivity by a proportional control thermostat in humans.
Topics: Adolescent; Adult; Body Temperature; Body Temperature Regulation; Bromocriptine; Circadian Rhythm; C | 2004 |
Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine.
Topics: Adrenocorticotropic Hormone; Adult; Antipsychotic Agents; Benzodiazepines; Circadian Rhythm; Growth | 2006 |
Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedative | 2007 |
Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedative | 2007 |
Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedative | 2007 |
Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedative | 2007 |
Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics.
Topics: Adult; Antipsychotic Agents; Circadian Rhythm; Female; Humans; Male; Melatonin; Schizophrenia | 1997 |
Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics.
Topics: Adult; Antipsychotic Agents; Circadian Rhythm; Female; Humans; Male; Melatonin; Schizophrenia | 1997 |
Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics.
Topics: Adult; Antipsychotic Agents; Circadian Rhythm; Female; Humans; Male; Melatonin; Schizophrenia | 1997 |
Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics.
Topics: Adult; Antipsychotic Agents; Circadian Rhythm; Female; Humans; Male; Melatonin; Schizophrenia | 1997 |
Melatonin improves sleep quality of patients with chronic schizophrenia.
Topics: Adult; Aged; Ambulatory Care; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Female; Hum | 2000 |
Is melatonin treatment effective for tardive dyskinesia?
Topics: Aged; Antioxidants; Antipsychotic Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Doub | 2000 |
First-night effect of melatonin treatment in patients with chronic schizophrenia.
Topics: Adult; Analysis of Variance; Antioxidants; Cross-Over Studies; Delayed-Action Preparations; Double-B | 2000 |
Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Antipsychotic Agents; Chronic Disease; Corpus Striatum | 2001 |
The relationship of pineal calcification and melatonin secretion to the pathophysiology of tardive dyskinesia and Tourette's syndrome.
Topics: Adult; Aged; Bipolar Disorder; Calcinosis; Dyskinesia, Drug-Induced; Female; Humans; Male; Melatonin | 1991 |
47 other studies available for melatonin and Schizophrenia
| Article | Year |
|---|---|
Reversal of Schizophrenia-like Symptoms and Cholinergic Alterations by Melatonin.
Topics: Animals; Cholinergic Agents; Disease Models, Animal; Humans; Male; Melatonin; Mice; Schizophrenia | 2019 |
Schizophrenia-like behavior is not altered by melatonin supplementation in rodents.
Topics: Animals; Behavior, Animal; Dietary Supplements; Disease Models, Animal; Melatonin; Rats; Rats, Wista | 2020 |
The role of melatonin in the neurodevelopmental etiology of schizophrenia: A study in human olfactory neuronal precursors.
Topics: Axons; Case-Control Studies; Cell Polarity; Cells, Cultured; Melatonin; Neuroepithelial Cells; Neuro | 2017 |
Melatonin attenuates behavioural deficits and reduces brain oxidative stress in a rodent model of schizophrenia.
Topics: Animals; Antioxidants; Brain; Disease Models, Animal; Interpersonal Relations; Locomotion; Male; Maz | 2017 |
Abnormally Increased Secretion in Olfactory Neuronal Precursors from a Case of Schizophrenia Is Modulated by Melatonin: A Pilot Study.
Topics: Actin Cytoskeleton; Adult; Calcium; Humans; Male; Melatonin; Neural Stem Cells; Olfactory Mucosa; Pi | 2017 |
Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia.
Topics: Adult; Attention; Circadian Rhythm; Female; Humans; Male; Melatonin; Middle Aged; Psychiatric Status | 2019 |
Potential role of some oxidant/antioxidant status parameters in prefrontal cortex of rat brain in an experimental psychosis model and the protective effects of melatonin.
Topics: Animals; Antioxidants; Disease Models, Animal; Dizocilpine Maleate; Glutathione Peroxidase; Male; Ma | 2014 |
Can the season of birth risk factor for schizophrenia be prevented by bright light treatment for the second trimester mother around the winter solstice?
Topics: Body Temperature; Circadian Rhythm; Corpus Striatum; Female; Hippocampus; Humans; Light; Maternal Ex | 2014 |
Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Immunologic Factors; Immunomodulation; | 2017 |
Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Hydroxyindoleacetic Acid; Kynurenine; Male; | 2010 |
Schizophrenia as a possible dysfunction of the suprachiasmatic nucleus.
Topics: Continuous Positive Airway Pressure; Delusions; Humans; Light; Melatonin; Models, Biological; Models | 2010 |
Schizophrenia, sleep disturbances and the suprachiasmatic nucleus: reduced nitric oxide synthase may matter.
Topics: Continuous Positive Airway Pressure; Delusions; Humans; Light; Melatonin; Models, Biological; Nitric | 2010 |
Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep.
Topics: Adult; Circadian Rhythm; Diseases in Twins; Humans; Male; Melatonin; Saliva; Schizophrenia; Twins, M | 2010 |
Prenatal corticosteroids: pretermer outcomes, stress, schizophrenia, multiple sclerosis and the developmental role of melatonin and vitamin D3.
Topics: Cholecalciferol; Dietary Supplements; Female; Humans; Hydrocortisone; Infant, Newborn; Melatonin; Mu | 2010 |
Sleep-wake cycles and cognitive functioning in schizophrenia.
Topics: Actigraphy; Adult; Circadian Rhythm; Cognition Disorders; Female; Humans; Male; Melatonin; Middle Ag | 2011 |
Bimodal rhythms of general conceptions and the birth-month phenomenon in schizophrenia, neural tube defects, and laterality: a solstitial hypothesis.
Topics: Antioxidants; Embryo Implantation; Epigenomics; Female; Functional Laterality; Humans; Melatonin; Ne | 2011 |
Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls.
Topics: Actigraphy; Adult; Case-Control Studies; Circadian Rhythm; Female; Humans; Male; Melatonin; Saliva; | 2011 |
Sleep and circadian rhythm disruption in schizophrenia.
Topics: Adult; Case-Control Studies; Female; Humans; Male; Melatonin; Monitoring, Ambulatory; Schizophrenia; | 2012 |
Chronic melatonin treatment reverses disruption of prepulse inhibition in pinealectomized and pinealectomized-plus-ovariectomized rats.
Topics: Animals; Avoidance Learning; Disease Models, Animal; Drug Administration Schedule; Exploratory Behav | 2013 |
Treating residual insomnia in schizophrenia: examining the options.
Topics: Antipsychotic Agents; Central Nervous System Depressants; Humans; Isoxazoles; Melatonin; Paliperidon | 2013 |
Restless nights, listless days.
Topics: Adolescent; Adult; Aged; Aging; Alzheimer Disease; Biological Clocks; Circadian Rhythm; Darkness; Hu | 2003 |
The suitability of actigraphy, diary data, and urinary melatonin profiles for quantitative assessment of sleep disturbances in schizophrenia: a case report.
Topics: Adult; Circadian Rhythm; Electronic Data Processing; Humans; Light; Male; Melatonin; Monitoring, Phy | 2006 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Energy Metabolism; Female; Lipid Meta | 2007 |
Melatonin/cortisol ratio in psychiatric illness.
Topics: Humans; Hydrocortisone; Male; Melatonin; Mental Disorders; Middle Aged; Schizophrenia | 1982 |
Melatonin and cortisol levels in psychiatric illness.
Topics: Depression; Diagnosis, Differential; Humans; Hydrocortisone; Melatonin; Mental Disorders; Schizophre | 1982 |
How information processing mode could affect prostaglandin E1 metabolism and lung inactivation: relevance of hemispheric specialization, neurotransmitter asymmetry and brain reactivity.
Topics: Alprostadil; beta-Endorphin; Brain; Cognition; Depression; Endorphins; Humans; Lung; Melatonin; Mode | 1984 |
Reduced nocturnal melatonin secretion in chronic schizophrenia: relationship to body weight.
Topics: Adult; Aged; Body Weight; Chronic Disease; Circadian Rhythm; Humans; Male; Melatonin; Middle Aged; S | 1982 |
Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings.
Topics: Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Melatonin; | 1980 |
Seasonal variation in the dexamethasone suppression test: a longitudinal study in chronic schizophrenics and in healthy subjects.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dexamethasone; F | 1994 |
Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Circadian Rhythm; Female; Growth Hormone; Humans; Hyp | 1994 |
[Melatonin excretion in patients with depression under the action of light of increased intensity].
Topics: Adolescent; Adult; Bipolar Disorder; Chronic Disease; Depressive Disorder, Major; Female; Fluorometr | 1995 |
Melatonin secretion during fluvoxamine treatment in medicated chronic schizophrenic patients: evidence for the development of tolerance to selective serotonin re-uptake inhibitor.
Topics: Adult; Biomarkers; Chronic Disease; Dose-Response Relationship, Drug; Drug Tolerance; Female; Fluvox | 1996 |
A schizophrenic patient with an arrhythmic circadian rest-activity cycle.
Topics: Adult; Antipsychotic Agents; Bed Rest; Body Temperature; Catatonia; Chronic Disease; Circadian Rhyth | 1997 |
Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients.
Topics: Adolescent; Adult; Circadian Rhythm; Dexamethasone; Humans; Hydrocortisone; Male; Melatonin; Schizop | 1998 |
A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia.
Topics: Adult; Circadian Rhythm; Female; Humans; Hydrocortisone; Male; Melatonin; Pineal Gland; Prolactin; R | 2001 |
Effect of propranolol on serum-melatonin.
Topics: Adult; Circadian Rhythm; Female; Humans; Melatonin; Propranolol; Schizophrenia | 1977 |
Schizophrenia: Reconciliation of the dopamine, prostaglandin, and opioid concepts and the role of the pineal.
Topics: Allergens; Dopamine; Endorphins; Enkephalins; Humans; Hypersensitivity; Melatonin; Pineal Gland; Pla | 1979 |
The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes.
Topics: Animals; Colchicine; Glucocorticoids; Humans; Liver Cirrhosis, Biliary; Melatonin; Models, Biologica | 1979 |
The pineal and psychiatry: a review.
Topics: Animals; Behavior, Animal; Brain; Electroencephalography; Humans; Melatonin; Pineal Gland; Psychotic | 1977 |
Abnormal EEG and calcification of the pineal gland in schizophrenia.
Topics: Adult; Aged; Calcinosis; Chlorpromazine; Electroencephalography; Female; Humans; Male; Melatonin; Mi | 1992 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients.
Topics: Adult; Chlorpromazine; Circadian Rhythm; Depressive Disorder; Drug Therapy, Combination; Female; Flu | 1991 |
Nocturnal melatonin and cortisol secretion in newly admitted psychiatric inpatients. Implications for affective disorders.
Topics: Adult; Circadian Rhythm; Depressive Disorder; Dexamethasone; Female; Humans; Hydrocortisone; Male; M | 1990 |
Abnormal melatonin response to 5-methoxypsoralen in dementia.
Topics: Adult; Aged; Aging; Dementia; Depressive Disorder; Female; Furocoumarins; Humans; Male; Melatonin; M | 1989 |
Nocturnal plasma melatonin levels in schizophrenic patients.
Topics: Adult; Circadian Rhythm; Female; Humans; Hydrocortisone; Male; Melatonin; Prolactin; Schizophrenia | 1989 |
The pathophysiology of enlarged ventricles in normal pressure communicating hydrocephalus and schizophrenia: a possible therapeutic role for melatonin.
Topics: Animals; Cerebral Ventricles; Disease Models, Animal; Humans; Hydrocephalus; Hydrocephalus, Normal P | 1987 |
Metabolism of exogenous melatonin in schizophrenic and non-schizophrenic volunteers.
Topics: Animals; Autoradiography; Brain Damage, Chronic; Carbon Isotopes; Chromatography, Gel; Chromatograph | 1969 |
Schizophrenia melanosis. Iatrogenic--congenital defect?
Topics: Animals; Anura; Copper; Diet; Female; Humans; Male; Melanins; Melanosis; Melatonin; Models, Biologic | 1968 |